Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1010837 | 0.88 | FKBP1A (0.47) | ALDH1A1 | |
| SCHEMBL1010262 | 0.87 | L3MBTL1 (0.43) | ALDH1A1ATML3MBTL1SLC6A4 | |
| SCHEMBL1012738 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL1011983 | 0.86 | SLC6A4 (0.54) | ALDH1A1KMT2ANPSR1SLC6A4 | |
| SCHEMBL1010278 | 0.83 | SLC6A4 (0.43) | ALDH1A1KMT2ASLC6A4 | |
| SCHEMBL7652967 | 0.81 | CYP2C19 (0.46) | ALDH1A1MEN1KMT2APOLBSLC6A4 | |
| SCHEMBL1012557 | 0.81 | HTR2C (0.51) | MEN1KMT2APKMNPSR1 | |
| SCHEMBL5466112 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL10258854 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 | |
| SCHEMBL3718243 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2APKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1118674-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | NIHON MEDIPHYSICS CO LTD (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | NIHON MEDI-PHYSICS CO., LTD. | 2003-04-03 | — | — | US | disclosed |
| US-6486323-B1 | Process for producing optically active tropinonemonocarboxylic acid derivative | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-11-26 | — | — | US | disclosed |
| EP-1118674-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE TROPINONE MONOCARBOXYLIC ACID DERIVATIVE | Nihon Medi-Physics Co., Ltd. (JP) | 2001-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065183-A1 | Process for producing optically active tropinonemonocarboxylic acid ester derivative | CES2, FTO, HAAO | ALDH1A1 57/4885MEN1 4875/4885KMT2A 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.